Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pink Sheet Team

Editorial Team

International

The policy and regulatory insights advantage for biopharma decision-makers around the globe.

Latest From Pink Sheet Team

Pink Sheet Podcast: Roctavian CRL, COVID-19 Vaccine Adcomm Expertise, Pandemic Inspection Policies

Pink Sheet reporters and editors discuss the surprise US complete response letter for a new gene therapy and the specialists who may be added to the FDA’s coronavirus vaccine advisory committee, and also look at facility inspections during the pandemic.

Complete Response Letters Coronavirus COVID-19

Coronavirus Notebook: Middle Ground Pricing As Moderna Reaches 100m Dose US Agreement

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.

Coronavirus COVID-19 Real-World Evidence

Pink Sheet Podcast: Fall Vaccine Adcom, COVID-19 Vaccine Price Trend, Plasma DTC Ad Questions

Pink Sheet reporters and editors dig into the emerging coronavirus vaccine regulatory schedule, look at vaccine purchasing trends, and consider the curious case of a federal government billboard encouraging convalescent plasma donations.

Coronavirus COVID-19 Vaccines

Pink Sheet Podcast: Vaccine Makers On Capitol Hill, User Fee Renewal Negotiations Begin

Pink Sheet reporters and editors discuss the performance of the leaders of several coronavirus vaccine manufacturers during a recent congressional hearing and consider proposed changes to the generic and prescription drug user fee programs.

Vaccines User Fees

BIO 2020 Notebook: Conversations On Rebates, Racism, And Remote Working

News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.

Business Strategies Coronavirus COVID-19

BIO 2020 Notebook: FDA's Hahn On COVID-19 Lessons To Be Learned; NIH's Fauci On Health Care Disparities; Pfizer's Young On Forgoing Gov't Vaccine Funds

News and views from day three of BIO Digital. US FDA Commissioner Hahn asks industry to help identify best regulatory lessons from the pandemic; Pfizer’s chief business officer explains how need to move quickly in vaccine partnership with BioNTech led to decision to forgo US funding.

Coronavirus COVID-19 Telehealth
See All
UsernamePublicRestriction

Register